四重特異性抗體市場:臨床試驗，專利技術，企業，市場趨勢(2023年)

Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023

出版日期: 2023年03月01日 | 出版商:

KuicK Research | 英文 78 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

由於四重特異性抗體的開發，在抗體的領域競爭變得激烈。對各種疾病和症狀，由於有可能提供更有針對性和有效的治療方法，許多企業對新世代抗體的研究開發進行高額投資。全球四重特異性抗體市場，由於更有效個別化的治療方法的需求高漲，今後數年預計大幅成長。

本報告提供全球四重特異性抗體市場相關調查，市場概要，以及四重特異性抗體的作用機制，癌症治療的作用，臨床試驗趨勢，及市場參與市場企業的競爭趨勢等資訊。

Global Tetraspecific Clinical Trials Landscape Insight
Global Tetraspecific Ongoing Clinical Trials By Company, Country, Indication & Phase
Tetraspecific Antibodies Proprietary Technologies By Company
Current Clinical Development & Future Commercialization Outlook
Tetraspecific Antibodies Mono & Combination Therapeutic Approaches
Competitive Landscape

The field of antibody therapeutics has been rapidly evolving in recent years, and one of the most exciting developments has been the transition from monoclonal to bispecific to the now emerging tetraspecific antibodies. These new generation antibodies have the potential to offer more targeted and effective therapies for a range of diseases and conditions. Traditionally, monoclonal antibodies have been used in the development of therapeutics. These are antibodies that are designed to target a single antigen or protein, and have been effective in treating a range of diseases, including cancer, autoimmune disorders, and infectious diseases.

However, tetraspecific antibodies offer a new level of selectivity and flexibility in targeted therapy approach. These multispecific antibodies are designed to target four different antigens or proteins, making them more targeted and effective in treating complex diseases and conditions. Tetraspecific antibodies can be used to target multiple pathways or receptors that are involved in disease progression, allowing for a more comprehensive and personalized approach to treatment. The potential of tetraspecific antibodies has been demonstrated in preclinical and clinical studies, with promising results in the treatment of cancer, autoimmune disorders, and infectious diseases. These antibodies have shown improved efficacy and safety compared to monoclonal antibodies, and have the potential to revolutionize the field of antibody therapeutics.

The swift change in the treatment landscape to tetraspecific antibodies represents an exciting new chapter in the field of antibody based therapies. With their increased specificity and versatility, tetraspecific antibodies have the potential to offer more targeted and effective therapies for a range of diseases and conditions. There are a number of companies that are currently developing tetraspecific antibodies, including some of the largest pharmaceutical companies in the world. These companies are investing heavily in research and development, and are working to bring these new therapies to market as quickly as possible. As research and development in this area continues, we can expect to see more exciting developments in the years to come.

The development of tetraspecific antibodies has created a highly competitive landscape in the field of antibody therapeutics. With their potential to offer more targeted and effective therapies for a range of diseases and conditions, many companies are investing heavily in the research and development of these new generation antibodies. The global market for tetraspecific antibodies is expected to grow significantly in the coming years, driven by increasing demand for more effective and personalized therapies.

For now, China, in particular, is poised to play a key role in the growth of the tetraspecific antibody market. Becoming the first country to step forward into the idea has given China an exciting advantage. Even though the notion is now adopted by US based pharmaceuticals companiesas well, China might still continue to lead the clinical development for a long time. The country's biotech industry has seen significant investment in recent years, with the government providing favorable policies and regulatory support to encourage innovation and growth. Chinese biotech companies have already made significant progress in the development of monoclonal antibodies and other innovative therapies, and are well-positioned to capitalize on the growing demand for tetraspecific antibodies. As such, the demand for tetraspecific antibodies is likely to increase in the coming years, as researchers and pharmaceutical companies work to develop more targeted and personalized treatments.

As per Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023 report findings, the future market outlook for tetraspecific antibodies looks promising. As the clinical research for tetraspecific antibodies continues to grow, we can expect to see more exciting developments in the years to come. With their potential to offer more targeted and effective therapies for a range of diseases and conditions, these new generation antibodies have the potential to revolutionize the field of antibody therapeutics and improve the lives of millions of people around the world. With its supportive regulatory environment and growing biotech industry, China along with its western counterparts is well-positioned to play a key role in the growth of this innovative and exciting sector. As such, investors and stakeholders should keep a close eye on the emerging opportunities in the tetraspecific antibody market.

1. Introduction to Tetraspecific Antibodies

1.1 Clinical Overview
1.2 History & Development

2. Tetraspecific Antibodies Mechanism Of Action

2.1 Multispecific Formats
2.2 Tetraspecific Antibodies Bringing Immune Cells & Target Cells Closer

3. Global Tetraspecific Ongoing Clinical Trials By Company, Country, Indication & Phase

3.1 By Company
3.2 By Country
3.3 By Indication
3.4 By Phase

4. Global Tetraspecific Ongoing Clinical Trials Insight

4.1 Research
4.2 Preclinical
4.3 Phase-I
4.4 Phase-II

5. Tetraspecific Antibodies Proprietary Technologies By Company

5.1 Available Proprietary Platforms
5.2 Potential Proprietary Platforms

6. Current Clinical Development & Future Commercialization Outlook

6.1 Current Scenario
6.2 Future Market Commercialization Outlook

7. Tetraspecific Antibodies Therapeutic Approaches

7.1 Tetraspecific Antibodies As Monotherapy
7.2 Tetraspecific Antibodies As Combinational Therapy
7.3 Tetraspecific Antibodies As Targeted Approach

8. Tetraspecific Antibodies Therapeutic Application In Cancer

8.1 Overview
8.2 Ongoing Research & Development

9. Competitive Landscape

9.1 Innate Pharma
9.2 ModeX Therapeutics (OPKO Health)
9.3 Ruijin Hospital
9.4 Sichuan Baili Pharmaceutical
9.5 SystImmune

簡介目錄圖表

List of Figures

Figure 1-1: FL518 - Structure
Figure 1-2: CRTB6 - Structure
Figure 1-3: LegoBody Tetraspecific Antibody Structure
Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage
Figure 2-1: Tetraspecific Antibody Structure
Figure 2-2: Tetraspecific Antibody Bringing T Cells & NK Cells In Close Proximity
Figure 3-1: Global - Tetraspecific Antibodies In Clinical Trials By Company, 2023
Figure 3-2: Global - Tetraspecific Antibodies In Clinical Trials By Country, 2023
Figure 3-3: Global - Tetraspecific Antibodies Clinical Trials By Indication, 2023
Figure 3-4: Global - Tetraspecific Antibodies In Clinical Trials By Phase, 2023
Figure 5-1: ANKET® Platform - Innate Pharma
Figure 5-2: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 5-3: STEALTH - ModeX Therapeutics
Figure 5-4: MSTAR - ModeX Therapeutics
Figure 5-5: Features of MSTAR
Figure 5-6: MATCH - Numab
Figure 5-7: Features of BiXAb
Figure 5-8: Zyngenia Technology Approach
Figure 5-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
Figure 5-2: Tetraspecific Antibody Engaging CD3 T cells
Figure 5-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
Figure 5-4: IPH6501 - Tetra-Specific NK Cell Engager
Figure 5-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
Figure 5-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
Figure 5-7: Novel Tetraspecific Format Developed By The Roche Pharma Research & Early Development
Figure 8-1: GNC-038 Phase I/II Study (NCT04606433) - Initiation & Completion Years
Figure 8-2: GNC-038 Phase I/II Study (NCT05192486) - Initiation & Completion Years
Figure 8-3: GNC-038 Phase I/II Study (NCT05485753) - Initiation & Completion Years
Figure 8-4: GNC-038 Phase I/II Study (NCT05623982) - Initiation & Completion Years
Figure 8-5: GNC-038 Phase I/II Study (NCT05627856) - Initiation & Completion Years
Figure 8-6: GNC-039 Phase I/II Study (NCT04794972) - Initiation & Completion Years
Figure 8-7: GNC-035 Phase I Study (NCT05039931) - Initiation & Completion Years